Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Rank in Stocks #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behรงet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Share Price
$207.15
Market Cap
$366.28B
Change (1 day)
0.99%
Change (1 year)
2.91%
Country
US
Trade AbbVie Inc. (ABBV)

Category

Stock split history for AbbVie Inc. (ABBV)
AbbVie Inc. stock (symbol: ABBV) underwent a total of 0 stock splits.
The most recent stock split occurred on Mar 26, 2026.
One ABBV share bought prior to Mar 26, 2026 would equal to 0 ABBV shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
4 x15
US
3 x2
GB
7 x432
US
2 x2
CH
7 x226
US